Trial Name News Today

The approval was based on the QUILT-3.032 study, which included 77 adults with carcinoma in situ with or without papillary tumors after a transurethral resection.

Tigilanol tiglate is a novel, small molecule drug for the intratumoral treatment of solid tumors, inducing tumor cell death and stimulating immune response.

In a phase 3 trial, none of the patients receiving nirogacestat reached median progression-free survival, indicating that it may effectively reduce disease progression.

Major barriers to care for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) can include navigating therapeutics and the cost of medications.

The Outlast Trials has received update 3 with a new trial being added, new challenges, and the time limited Halloween event Project Geister. There has